PCRX — Pacira Biosciences Share News
0.000.00%
Last trade - 00:00- $878.64m
- $1.04bn
- $726.41m
Brief: Pacira Biosciences Files Exparel Patent Infringement Lawsuits Against The Whiteoak Group And Qilu Pharmaceutical
Brief: Doma Perpetual Urges Pacira Biosciences To Immediately Explore Sale Of The Business
Pacira Biosciences Q3 revenue misses estimates
Brief: Pacira Biosciences Q3 Revenue USD 179.5 Million Vs. IBES Estimate USD 182.9 Million
Brief: Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
Brief: Pacira Signs Exclusive License With AmacaThera For Long-Acting Analgesic For Postsurgical Pain Relief
Brief: Pacira Biosciences Inc - Receives Paragraph Iv Notice From Qilu Pharmaceutical
Brief: Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL
Brief: Pacira Biosciences Reports Inducement Grants
Brief: Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Pacira Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Pacira BioSciences' Q2 revenue misses estimates
Pacira Biosciences Inc expected to post earnings of 71 cents a share - Earnings Preview
Brief: Pacira Biosciences Announces Strategic Collaboration To Significantly Expand Zilretta Promotional Efforts
U.S. STOCKS ON THE MOVE-Tesla, AbbVie, McDonald's
U.S. STOCKS ON THE MOVE-Copper miners, AMD, DallasNews
U.S. STOCKS ON THE MOVE-Huntington Ingalls, Nucor, Estee Lauder
Pacira BioSciences falls after co cuts jobs amid manufacturing upgrade
Brief: Pacira BioSciences Announces Workforce Reduction